近日,Immunocore宣布了其候选产品IMC-C103C在特定实体瘤中的1期临床数据。IMC-C103C是一款基于TCR结构,靶向表达黑色素瘤相关抗原A4(MAGE-A4)肿瘤抗原的双特异性分子。 2018年,罗氏公司旗下Genentech公司达成...
Immunocore; Financial Interests, Institutional, Principal Investigator: Incyte; Financial Interests, Institutional, Principal Investigator: Janssen; Financial Interests, Institutional, Principal Investigator: Kymab Ltd; Financial Interests, Institutional, Principal Investigator: Millenium Pharmaceuticals/Takeda; Financia...